How Does Praluent Work? Mechanism of Action Explained in Plain English

Praluent (alirocumab) lowers LDL cholesterol by up to 63% — far more than most other cholesterol medications. To understand why it's so effective, it helps to understand how your liver normally removes cholesterol from the bloodstream, and how the PCSK9 enzyme disrupts that process.

Step 1: Your Liver Is the Cholesterol Recycler

Your liver is the primary site where LDL ("bad") cholesterol is removed from your blood. On the surface of liver cells are specialized proteins called LDL receptors. These receptors work like tiny hooks that grab onto LDL particles floating in the bloodstream, pull them into the liver cell, and break them down.

After grabbing an LDL particle, the receptor is supposed to be released back to the surface of the liver cell — recycled — ready to grab another LDL particle. The more receptors your liver has cycling on its surface, the more LDL it can remove from your blood.

Step 2: The Problem with PCSK9

Here's where things go wrong for many people. Your liver also produces an enzyme called PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9's job is to prevent LDL receptors from being recycled back to the liver surface.

When PCSK9 binds to an LDL receptor, it tags that receptor for destruction inside the liver cell. The receptor gets broken down instead of recycled. This reduces the total number of LDL receptors available to clear cholesterol from the blood — causing LDL levels to rise.

In people with familial hypercholesterolemia (FH), genetic mutations often result in either too much PCSK9 activity or too few functional LDL receptors — both leading to dramatically elevated LDL-C from birth.

Step 3: How Praluent Blocks PCSK9

Praluent (alirocumab) is a human monoclonal antibody — a Y-shaped protein specifically engineered to bind to the PCSK9 enzyme and block it from doing its job.

When you inject Praluent, it circulates in your bloodstream and attaches itself to free PCSK9 molecules. Once PCSK9 is bound by Praluent, it can no longer attach to LDL receptors. That means LDL receptors don't get destroyed — they get recycled back to the surface of liver cells, where they can capture and remove more LDL from the blood.

The result: more LDL receptors on liver surfaces → more LDL captured from the blood → significantly lower LDL-C levels. Following a single injection, maximal suppression of free PCSK9 occurs within just 4 to 8 hours.

How Praluent Differs from Statins

Statins (like atorvastatin and rosuvastatin) lower cholesterol by blocking HMG-CoA reductase — an enzyme involved in cholesterol synthesis inside the liver. They reduce how much cholesterol the liver makes in the first place.

Praluent takes a completely different approach: it doesn't reduce cholesterol production — it increases cholesterol clearance. By blocking PCSK9, Praluent allows more LDL receptors to remain active, so the liver clears existing LDL from the blood more efficiently. These two mechanisms are complementary, which is why Praluent works well in combination with statins.

Interestingly, statins actually increase PCSK9 production as a side effect of lowering cholesterol synthesis — which limits some of their LDL-C lowering effect. Praluent directly counters this by blocking the PCSK9 that statins inadvertently produce, making the combination more powerful than either drug alone.

39,483+ patients found their medications in stock

39K+

Find Praluent In Stock Today →

How Effective Is It?

The numbers are striking. In clinical trials, Praluent reduces LDL-C by approximately 45–63% from baseline when added to maximally tolerated statin therapy. In the ODYSSEY OUTCOMES trial (18,924 patients), patients on alirocumab achieved an average LDL-C of 53.3 mg/dL — compared to 101.4 mg/dL in the placebo group. That 54.7% reduction translated to a 15% lower risk of major cardiovascular events.

Why Is Praluent Injected, Not Swallowed?

Praluent is a large protein molecule — a monoclonal antibody with a molecular weight of approximately 146 kDa. If taken orally, it would be broken down in the digestive system before reaching the bloodstream, just like any dietary protein. Subcutaneous injection allows it to be absorbed directly into the bloodstream, where it can circulate and bind PCSK9.

The body eventually degrades Praluent into small peptides and amino acids — the same building blocks of any protein. This is why it has very few drug-drug interactions; it doesn't go through the same liver enzyme pathways as most small-molecule drugs.

For more on what Praluent treats, its dosing schedule, and how to get it filled, see our guide: What Is Praluent? Uses, Dosage, and What You Need to Know in 2026.

If you've been prescribed Praluent and need help finding it at a pharmacy near you, medfinder can locate pharmacies with it in stock.